Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
Immunization of Macaca fascicularis with inactivated SIV preparations: a) challenge with human- or monkey-derived-SIV; b) effects of longer immunization schedule.
Symp Nonhum Primate Models AIDS. 1992 Nov 17-20;10:abstract no. 130. Unique Identifier : AIDSLINE PRIM10/93200973 Titti F; Koanga Mogtomo L; Borsetti A; Geraci A; Sernicola L; Panzini G; Turillazzi GP; Pace M; Baroncelli S; Zamarchi R; et al; Istituto Superiore di Sanita, Rome, Italy.
Abstract:
OBJECTIVE: To evaluate i) the efficacy of two different vaccine preparations and schedules of immunization, ii) whether there is a different protection against human (32H) or monkey-derived-SIV, iii) the role of anti-cellular antibodies in protective immunity. RESULTS: 5 males Macaca fascicularis (Mf) (group A) were immunized on week 0, 4, 8 with 0.1 mg/dose of formalin inactivated SIVmac251/32H in Ribi adjuvant and were then challenged with 10 MID50 of SIVmac251/32H on week 10. All monkeys were protected from infection. They were monitored for 7 months for serology, viral isolation, and PCR-DNA; 3/5 showed in vitro spontaneous anti-SIV Ab production shortly after boosting, and PWM-induced anti-SIV Ab synthesis was documented in 3/5. Further the vaccinated monkeys received three boosters (0.1, 0.5, 0.5 mg) on weeks 28, 46, 50 p.c. and two weeks later were rechallenged with 10 MID50 of SIVmac251 monkey derived. No protection from infection was observed as judged by specific antibody anamnestic response, viral reisolation and PCR-DNA analysis at one month p.c. 5 females Mf were immunized (0, 2, 4, 6 weeks) with 0.25 mg/dose of whole formalin inactivated SIVmac251 (the first 2 doses in incomplete Freund's adjuvant). All monkeys were repeatedly reboostered (4-6 doses) with the same antigen during two years. Two weeks after the last boost the monkeys were challenged either with SIVmac251/32H (3 Mf-group B), or with SIVmac251 monkey derived (2 Mf-group C). Virus was reisolated from 2/2 (group C) but not from 2/3 monkeys (group B) at one month p.c. Plasmas (pre-immune, immune, after the 1st and 2nd challenge) of all monkeys were assayed by FACS analysis versus C8166 cells. Reactivity to cell surface receptor(s) was present but appears to be not significantly related to the status (protection/infection) of the monkeys.
Keywords: Animal Comparative Study Female Human Immunity, Cellular Immunization Schedule Immunization, Secondary Macaca fascicularis Male SIV/*IMMUNOLOGY/ISOLATION & PURIF T-Lymphocytes/IMMUNOLOGY Time Factors Vaccines, Inactivated/ADMINISTRATION & DOSAGE/*IMMUNOLOGY Viral Vaccines/ADMINISTRATION & DOSAGE/*IMMUNOLOGY ABSTRACT 930630
M9361047
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
